Edmond DE Rothschild Holding S.A. grew its position in shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 10.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 260,300 shares of the biotechnology company’s stock after purchasing an additional 25,000 shares during the period. Edmond DE Rothschild Holding S.A. owned 0.26% of Momenta Pharmaceuticals worth $2,874,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in MNTA. BlackRock Inc. lifted its holdings in shares of Momenta Pharmaceuticals by 14.0% during the 4th quarter. BlackRock Inc. now owns 13,775,141 shares of the biotechnology company’s stock worth $152,079,000 after acquiring an additional 1,694,797 shares during the period. Westfield Capital Management Co. LP purchased a new position in shares of Momenta Pharmaceuticals during the 4th quarter worth about $7,036,000. Oregon Public Employees Retirement Fund purchased a new position in shares of Momenta Pharmaceuticals during the 4th quarter worth about $37,000. Monashee Investment Management LLC purchased a new position in shares of Momenta Pharmaceuticals during the 4th quarter worth about $3,864,000. Finally, Vanguard Group Inc lifted its holdings in shares of Momenta Pharmaceuticals by 3.8% during the 3rd quarter. Vanguard Group Inc now owns 7,597,950 shares of the biotechnology company’s stock worth $199,827,000 after acquiring an additional 280,177 shares during the period. 95.12% of the stock is currently owned by institutional investors.
NASDAQ MNTA opened at $14.00 on Friday. Momenta Pharmaceuticals, Inc. has a one year low of $9.55 and a one year high of $32.20. The company has a market capitalization of $1.37 billion, a P/E ratio of -6.90 and a beta of 2.24.
In other Momenta Pharmaceuticals news, insider Jo Ann Beltramello sold 8,377 shares of the stock in a transaction that occurred on Tuesday, February 19th. The shares were sold at an average price of $13.62, for a total value of $114,094.74. Following the completion of the sale, the insider now owns 141,736 shares of the company’s stock, valued at $1,930,444.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Craig A. Wheeler sold 2,601 shares of the stock in a transaction that occurred on Friday, February 8th. The shares were sold at an average price of $11.76, for a total transaction of $30,587.76. Following the completion of the sale, the chief executive officer now directly owns 186,174 shares of the company’s stock, valued at approximately $2,189,406.24. The disclosure for this sale can be found here. Insiders sold 31,944 shares of company stock worth $416,487 in the last 90 days. 3.70% of the stock is currently owned by insiders.
MNTA has been the topic of several research reports. Stifel Nicolaus restated a “buy” rating on shares of Momenta Pharmaceuticals in a report on Tuesday, January 8th. Zacks Investment Research upgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a report on Thursday, January 3rd. BidaskClub upgraded shares of Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 20th. ValuEngine lowered shares of Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 2nd. Finally, Cantor Fitzgerald restated a “hold” rating and issued a $16.00 price target on shares of Momenta Pharmaceuticals in a report on Friday, February 22nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $24.00.
Momenta Pharmaceuticals Company Profile
Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.
Read More: Buy-Side Analysts
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.